Boehringer Ingelheim receives approval for SENVELGO in Europe: the first oral liquid medication for diabetic cats Read more
Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma Read more
Vivodyne Announces $38 Million Seed Financing Led by Khosla Ventures to Develop Lab-Grown Human Organs Read more
FDA Grants Orphan Drug Designation to NeoImmuneTech’s NT-I7 for the Treatment of Acute Radiation Syndrome Read more
Janssen Submits Supplemental Biologics License Application to U.S. FDA Seeking Approval of RYBREVANT (amivantamab-vmjw) Plus Chemotherapy for the Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer Who Progressed on or after Osimertinib Read more
Genentech and NVIDIA Enter Into Strategic AI Research Collaboration to Accelerate Drug Discovery and Development Read more
Chiesi Group signed a License Agreement with Haisco Pharmaceutical to develop, manufacture, and commercialise a novel, reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis Read more
Truqap (capivasertib) plus Faslodex approved in the US for patients with advanced HR-positive breast cancer Read more
BeiGene Receives European Commission Approval for BRUKINSA (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma Read more